CD274 and non-small cell lung carcinoma: In the phase III open-label KEYNOTE-024 trial [31], metastatic NSCLC tumors with a PD-L1 tumor proportion score (TPS) ≥50% showed improved progression-free survival (PFS) (Hazard ratio (HR) 0.50; 95% confidence interval (CI) 0.37–0.68), p < 0.001), and overall response rate (ORR) (44.8% vs. 27.8%) with pembrolizumab.